EUR/USD Price Analysis: Bulls continue to defend 1.21
EUR/USD continues to hold the psychological support of 1.21 for the third straight day despite the dovish European Central Bank (ECB) expectations. Wi
Read More »More ups than downs
A reflation trade is finding a foothold, joining vaccine inspired risk-on flows to drive sovereign yields higher. Treasuries have led the charge with the 1.75% 30-year yield the highest since…
Read More »Europe’s challenges
Europe is in the middle of a second wave of Covid-19 infections. The prospect of another hit to the economy in Q4 still leaves ECB and fiscal authorities in crisis…
Read More »Events to Look Out for Next Week
Its a short but also busy week, as the Thanksgiving holiday will keep US markets close on Friday. From a data perspective, it will definitely be an eventful week Monday…
Read More »EUR eyes yields and stimulus moves
It has been a week of big moves for both bond and stock markets and investors have turned much more optimistic on the outlook thanks to virus headlines, but also…
Read More »European GDPs surprise to the upside, Equities recover a tad
Eurozone GDP rebounded 12.7% q/q in the third quarter, more than initially expected, but not a total surprise after German, French, Italian and Spanish numbers all surprised on the upside…
Read More »Euro Forecast: EUR/USD Outlook Bleak if 1.16 Support Breaks
A steep fall in EUR/USD is on the cards if strong support at 1.16 breaks after last week’s strong hint by the ECB that it’s planning still more stimulus for…
Read More »Strong demand for EU’s First Social Bonds
The Euro has slipped back into the outperforming lane in showing a 0.3% gain on the dollar, a 0.5% advance versus the Yen and gains against Sterling and the Dollar…
Read More »Events to Look Out for Next Week
A busy week starts quite early with ECB President Lagarde and BoE Governor Balay speaking Sunday evening. The uncertain second US Presidential debate will be the highlight next week as…
Read More »Equity markets rally loses some momentum in EU session
Risk aversion picked up again, underpinned by negative vaccine news amid reports that Johnson & Johnson halted its Covid-19 trial due to “unexplained illness”. The December 10-year Bund future is…
Read More »